Abstract
Nephrotoxicity is an important clinical side effect of the chemotherapeutic agent ifosfamide. This medication is activated by the hepatic cytochrome P450 system with potentially toxic metabolites produced through both ring hydroxylation and chloroethyl side chain oxidation pathways. Using an isolated perfused rat kidney preparation, we examined the possibility that renal metabolism of ifosfamide also occurs. Renal function before and after addition of ifosfamide to perfusate was not significantly different. After addition of ifosfamike to the perfusate, the metabolites N2-dechloroethylifosfamide, N3-dechloroethylifosfamide, and isophasphoramide mustard were recovered from urine and renal venous effluent. These results provide the first demonstration of ifosfamide metabolism by the kidney and suggest the possibility that intratenal metabolism may contribute to nephrotoxicity.
Footnotes
-
Send reprint requests to: James Springate, M.D., Division of Nephrology, The Children’s Hospital, 219 Bryant Street, Buffalo, NY 14222.
-
This research was supported by grants from the Association for Research of Childhood Cancer and the James H. Cummings Foundation.
- Abbreviations used are::
- IF
- ifosfamide
- N2D
- N2-dechloroethylIF
- N3D
- N3-dechloroethyl
- IPM
- isophosphoramide mustard
- Received February 24, 1997.
- Accepted May 19, 1997.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|